Frailty and Metabolic Syndrome cast gaunt (and flabby) shadows over our aging world; the need for new therapeutics has never been so urgent.
Follistatin gene therapy addresses two pressing epidemics: frailty from sarcopenia (age-related muscle loss) and Metabolic Syndrome — a constellation of issues including insulin insensitivity, hypertension, high cholesterol, and excess body fat (Cornier, 2008).
Heart disease is the leading cause of death in the developed world; aging and Metabolic Syndrome are its primary contributors.
Follistatin gene therapy has been successfully used in patients with muscular dystrophy (Mendel, 2012; Mendel, 2015).